These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37748124)

  • 21. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Ali A; Hoyle A; Haran ÁM; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Dearnaley D; Attard G; Gillessen S; Parmar MKB; Parker CC; Sydes MR; James ND; Clarke NW
    JAMA Oncol; 2021 Apr; 7(4):555-563. PubMed ID: 33599706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial.
    Seider MJ; Pugh SL; Langer C; Wyatt G; Demas W; Rashtian A; Clausen CL; Derdel JD; Cleary SF; Peters CA; Ramalingam A; Clarkson JE; Tomblyn M; Rabinovitch RA; Kachnic LA; Berk LB;
    Ann Nucl Med; 2018 Oct; 32(8):553-560. PubMed ID: 30094545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).
    Katakami N; Nishimura T; Hidaka Y; Hata A; Nishino K; Mori M; Hirashima T; Takase N; Kaneda T; Ohnishi H; Morita S; Hatachi Y
    Lung Cancer; 2023 Aug; 182():107261. PubMed ID: 37307753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
    Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
    Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
    Gridelli C; de Castro Carpeno J; Dingemans AC; Griesinger F; Grossi F; Langer C; Ohe Y; Syrigos K; Thatcher N; Das-Gupta A; Truman M; Donica M; Smoljanovic V; Bennouna J
    JAMA Oncol; 2018 Dec; 4(12):e183486. PubMed ID: 30177994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.
    Élez E; Kocáková I; Höhler T; Martens UM; Bokemeyer C; Van Cutsem E; Melichar B; Smakal M; Csőszi T; Topuzov E; Orlova R; Tjulandin S; Rivera F; Straub J; Bruns R; Quaratino S; Tabernero J
    Ann Oncol; 2015 Jan; 26(1):132-140. PubMed ID: 25319061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events.
    Yaldo A; Wen L; Ogbonnaya A; Valderrama A; Kish J; Eaddy M; Kreilick C; Tangirala K; Shields K
    Clin Ther; 2016 Aug; 38(8):1880-9. PubMed ID: 27478111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
    Mason MD; Clarke NW; James ND; Dearnaley DP; Spears MR; Ritchie AWS; Attard G; Cross W; Jones RJ; Parker CC; Russell JM; Thalmann GN; Schiavone F; Cassoly E; Matheson D; Millman R; Rentsch CA; Barber J; Gilson C; Ibrahim A; Logue J; Lydon A; Nikapota AD; O'Sullivan JM; Porfiri E; Protheroe A; Srihari NN; Tsang D; Wagstaff J; Wallace J; Walmsley C; Parmar MKB; Sydes MR;
    J Clin Oncol; 2017 May; 35(14):1530-1541. PubMed ID: 28300506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases-A Phase 2 Randomized Controlled Trial Within a Prospective Cohort.
    Pielkenrood BJ; van der Velden JM; van der Linden YM; Bartels MMT; Kasperts N; Verhoeff JJC; Eppinga WSC; Gal R; Verlaan JJ; Verkooijen HML
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):358-367. PubMed ID: 33333200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
    Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
    Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
    Beer TM; Kwon ED; Drake CG; Fizazi K; Logothetis C; Gravis G; Ganju V; Polikoff J; Saad F; Humanski P; Piulats JM; Gonzalez Mella P; Ng SS; Jaeger D; Parnis FX; Franke FA; Puente J; Carvajal R; Sengeløv L; McHenry MB; Varma A; van den Eertwegh AJ; Gerritsen W
    J Clin Oncol; 2017 Jan; 35(1):40-47. PubMed ID: 28034081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
    Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Could conventionally fractionated radiation therapy coupled with stereotactic body radiation therapy improve local control in bone oligometastases?
    Py JF; Salleron J; Vogin G; Courrech F; Teixeira P; Colnat-Coulbois S; Baumard F; Thureau S; Supiot S; Peiffert D; Oldrini G; Faivre JC
    Cancer Radiother; 2023 Feb; 27(1):1-10. PubMed ID: 36641333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
    Addison CL; Pond GR; Cochrane B; Zhao H; Chia SK; Levine MN; Clemons M
    J Bone Oncol; 2015 Jun; 4(2):47-53. PubMed ID: 26579488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
    Trinkaus M; Simmons C; Myers J; Dranatisaris G; Clemons M
    Support Care Cancer; 2010 Feb; 18(2):197-203. PubMed ID: 19424729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
    Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
    Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.
    Rief H; Omlor G; Akbar M; Bruckner T; Rieken S; Förster R; Schlampp I; Welzel T; Bostel T; Roth HJ; Debus J
    BMC Cancer; 2016 Mar; 16():231. PubMed ID: 26983672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Skeletal-related events due to bone metastases from differentiated thyroid cancer.
    Farooki A; Leung V; Tala H; Tuttle RM
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2433-9. PubMed ID: 22564664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.